<div class="xbrl-content"> <h3>Quarterly report pursuant to Section 13 or 15(d)</h3> <div id="xbrl-menu-top"> <div class="navigation"> <ul class="xbrl-sf-menu"> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3082">Cover</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3082">Document And Entity Information</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3083">Financial Statements</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3083">CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3084">CONDENSED CONSOLIDATED BALANCE SHEETS</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3085">CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3086">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3087">Notes to Financial Statements</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3087">Basis of Presentation and Summary of Significant Accounting Policies</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3088">Revenue Recognition</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3089">Selected Balance Sheet Data</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3090">Acquisitions</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3091">Fair Value Measurements</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3092">Debt and Other Financing Arrangements</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3093">Leases</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3094">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3095">Earnings Per Share</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3096">Share-based Compensation</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3097">Other Income / (Expense)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3098">Income Taxes</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3099">Segment Information</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3100">Subsequent Events</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3101">Pay vs Performance Disclosure</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3102">Insider Trading Arrangements</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3103">Accounting Policies</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3103">Basis of Presentation and Summary of Significant Accounting Policies (Policies)</a></li> </ul> </li> <li> <a class="menu-item " href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3104">Notes Tables</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3104">Basis of Presentation and Summary of Significant Accounting Policies (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3105">Revenue Recognition (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3106">Selected Balance Sheet Data (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3107">Acquisitions (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3108">Fair Value Measurements (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3109">Leases (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3110">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3111">Earnings Per Share (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3112">Other Income / (Expense) (Tables)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3113">Segment Information (Tables)</a></li> </ul> </li> <li> <a class="menu-item current" href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3114">Notes Details</a> <ul class="submenu"> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3114">Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3115">Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3116">Revenue Recognition - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3117">Revenue Recognition - Disaggregation of Revenue (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3118">Selected Balance Sheet Data - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3119">Selected Balance Sheet Data - Inventories (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3120">Selected Balance Sheet Data - Property and Equipment (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3121">Selected Balance Sheet Data - Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3122">Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3123">Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3124">Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3125">Selected Balance Sheet Data - Other Assets (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3126">Acquisitions - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3127">Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3128">Fair Value Measurements - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3129">Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3130">Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3131">Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3132">Debt and Other Financing Arrangements - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3133">Leases - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3134">Leases - Balance Sheet Classification (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3135">Leases - Cash Paid (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3136">Leases - Fair Value of the Lease Liability by Payment Date (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3137">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3138">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3139">Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3140">Earnings Per Share - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3141">Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3142">Share-based Compensation (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3143">Other Income / (Expense) - Narrative (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3144">Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3145">Income Taxes (Details)</a></li> <li><a href="https://investors.bio-techne.com/all-sec-filings/xbrl_doc_only/3146">Segment Information - Financial Information Relating to Reportable Segments (Details)</a></li> </ul> </li> </ul> </div> </div> <div class="spr-xbrl-document"> <h4>Debt and Other Financing Arrangements - Narrative (Details)</h4> <title></title> <span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45979231726048"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Other Financing Arrangements - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="1">3 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Aug. 31, 2022</div></th> <th class="th"><div>Sep. 30, 2023</div></th> <th class="th"><div>Sep. 30, 2024</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings under line-of-credit agreement</a></td> <td class="text">聽<span></span> </td> <td class="nump">$ 160,000<span></span> </td> <td class="text">聽<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tech_AmendedCreditAgreementMember', window );">Amended Credit Agreement</a></td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of Credit, Current</a></td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> <td class="nump">$ 300,000<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Amended Credit Agreement</a></td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td> <td class="nump">$ 1,000,000<span></span> </td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tech_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Line of Credit Facility, Additional Borrowing Capacity</a></td> <td class="nump">$ 400,000<span></span> </td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</a></td> <td class="nump">0.10%<span></span> </td> <td class="text">聽<span></span> </td> <td class="text">聽<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tech_LineOfCreditFacilityAdditionalBorrowingCapacity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element representing the additional borrowing capacity under a line of credit.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">tech_LineOfCreditFacilityAdditionalBorrowingCapacity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>tech_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tech_AmendedCreditAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tech_AmendedCreditAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> <div style="clear:both;"></div> </div> </div> <link rel="stylesheet" href="//investors.bio-techne.com/stylesheets/xbrl.css" type="text/css">